A potent, selective BCR-ABL inhibitor that fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib (Cat. No. 1625-100, 1000).  Nilotinib is not only more potent than imatinib against wild-type BCR-ABL (IC₅₀ < 30 nM), but also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.